Allosteric Kinase Modulators via PIF Pocket Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current protein kinase inhibitors primarily target the ATP binding site, leading to non-selective binding to other ATP-binding enzymes, resulting in side effects and limited potency due to high intracellular ATP levels, with few true allosteric inhibitors available that can activate or inhibit protein kinases effectively.
Innovation Solution
Development of small molecule compounds that allosterically regulate AGC protein kinases and the Aurora family by binding to regulatory sites, such as the PIF pocket, to modulate their activity, allowing for selective activation or inhibition of these kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds target the ATP binding site of protein kinases, then they can effectively inhibit kinase activity, but they bind non-selectively to other ATP-binding enzymes causing side effects
Solution Approach 1:
The patent extracts the inhibitor binding site from the ATP binding site by targeting allosteric regulatory sites (such as the PIF pocket) on protein kinases. This allows the compound to modulate kinase activity without competing with ATP for the catalytic site, thereby avoiding non-selective binding to other ATP-binding enzymes while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent uses allosteric regulatory sites as intermediaries to indirectly modulate kinase activity. By binding to these remote regulatory sites, the compounds exert their effects through conformational changes that propagate to the catalytic site, providing selective modulation without direct competition with ATP at the catalytic site.
2Power
If ATP-competitive inhibitors are used, then they can bind to the catalytic site, but their potency drops significantly in cells due to high intracellular ATP levels
Solution Approach 1:
The patent removes the dependency on ATP competition by extracting the binding target from the ATP binding site to allosteric regulatory sites. This allows the inhibitors to maintain high potency in cellular environments where ATP concentrations are millimolar, as they do not need to compete with ATP for binding.
Solution Approach 2:
The patent shifts the binding location from the two-dimensional ATP binding pocket to three-dimensional allosteric regulatory sites on the kinase surface. This dimensional shift allows the compounds to bind with high affinity without being displaced by ATP, thereby maintaining cellular potency.
3Object-affected harmful factors
If compounds are designed to be selective for specific kinases, then side effects are reduced, but the medicinal chemistry process becomes difficult and time-consuming
Solution Approach 1:
The patent exploits the universal presence of conserved allosteric regulatory sites (such as the PIF pocket) across multiple kinase families. A single compound design targeting these conserved sites can achieve broad selectivity across kinase families, reducing the need for extensive medicinal chemistry optimization for each individual kinase target.
Solution Approach 2:
The patent changes the binding parameter from ATP-competitive binding to allosteric binding at conserved regulatory sites. This parameter change inherently provides selectivity because the allosteric sites have distinct structural features that can be targeted more easily than the highly conserved ATP binding sites, thereby reducing drug development time.
Data Source
AI summary
The invention provides specific small molecule compounds that allosterically regulate the activity or modulate protein-protein interactions of AGC protein kinases and the Aurora family of protein kinases, methods for their production, pharmaceutical compositions comprising same, and their use for preparing medicaments for the treatment and prevention of diseases related to abnormal activities of AGC protein kinases or of protein kinases of the Aurora family.